Labopharm, Inc., a specialty pharmaceutical company, develops drugs by incorporating its proprietary controlled-release technologies. It offers a once-daily formulation of the pain-killer, tramadol to treat patients with moderate to severe pain in the United States, Europe, Mexico, Latin America, and the Caribbean. The company conducts Phase III clinical studies for once-daily formulations of Trazodone, an antidepressant; Phase I clinical studies for Tramadol combination products to meter the dispersion of two active ingredients for clinically beneficial interaction between the drugs; Phase I clinical studies for abuse resistant formulations of an opioid drug to provide patient safety; and Phase I clinical studies for anti-inflammatory products. It also develops a once-daily formulation of betahistine, an oral histamine analogue, for the treatment of the symptoms related to Meniere's disease, a disorder characterized by recurrent vertigo and hearing loss; and DDS-2001, an undisclosed formulation in Phase I studies. Labopharm's products are based on Contramid platform, a drug delivery technology that meters the release of drugs from orally administered solid dosage forms, such as tablets. In addition, it develops polymeric nano-delivery systems for delivery of water-insoluble and poorly bio-available drugs, as well as for developing intravenous and oral formulation product candidates. The company was founded in 1990. It was formerly known as Centre de recherche appliquee pharmaceutique CRAP, inc. and changed its name to Labopharm, Inc. in 1994. Labopharm, Inc. is headquartered in Laval, Canada.